Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Locally Advanced Prostate Cancer

Treatments: Drug: Iressa

Study type: Interventional

Funder types: Industry

Identifiers

NCT00319787

1839IL/0129

Details and patient eligibility

About

The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate specific antigen (PSA) levels.

Sex: Male

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 to 80 years of age. Men with histologically confirmed locally advanced prostatic adenocarcinoma

Exclusion criteria

• No prior treatment for prostate cancer, including surgery, radiotherapy, cryotherapy or thermotherapy. No abnormal laboratory values. No co-existing malignancies and any other significant clinical disorder or laboratory finding.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind